Recently,Richter et al.[1]revealed the potential functions of the interaction between the serine/threonine kinase Tank-binding kinase 1（TBK1）and the autophagy receptor optineurin（OPTN）.The TBK1-OPTN axis targets d...Recently,Richter et al.[1]revealed the potential functions of the interaction between the serine/threonine kinase Tank-binding kinase 1（TBK1）and the autophagy receptor optineurin（OPTN）.The TBK1-OPTN axis targets damaged mitochondria for degradation via PINK1/parkin-mediated mitophagy[2,3].Indeed,TBK1 can phosphorylate OPTN at Ser177,Ser473,or Ser513 to enhance the binding capacity of OPTN with poly-ubiquitin（poly-UB）chains.Conversely,展开更多
Chimeric antigen receptor T cell therapy has revolutionized cancer treatment,but its efficacy remains constrained by the immunosuppressive tumor microenvironment.Emerging evidence identifies the neuro-immune-cancer ax...Chimeric antigen receptor T cell therapy has revolutionized cancer treatment,but its efficacy remains constrained by the immunosuppressive tumor microenvironment.Emerging evidence identifies the neuro-immune-cancer axis as a critical modulator of tumor microenvironment dynamics,offering novel opportunities to reshape immune responses.Neural signaling influences chimeric antigen receptor T cell function,yet therapeutic strategies targeting this axis remain largely unexplored.展开更多
基金supported by the National Natural Science Foundation of China(81470434,81503074,and81670265)the Science and Technology Project of Hunan Province,China(2015RS4040)+1 种基金the Administration of Traditional Chinese Medicine of Hunan Province,China(201578)the Health and Family-planning Commission of Hunan Province,China(B2015-48)
文摘Recently,Richter et al.[1]revealed the potential functions of the interaction between the serine/threonine kinase Tank-binding kinase 1（TBK1）and the autophagy receptor optineurin（OPTN）.The TBK1-OPTN axis targets damaged mitochondria for degradation via PINK1/parkin-mediated mitophagy[2,3].Indeed,TBK1 can phosphorylate OPTN at Ser177,Ser473,or Ser513 to enhance the binding capacity of OPTN with poly-ubiquitin（poly-UB）chains.Conversely,
基金supported by the National Natural Science Foundation of China(82530008)。
文摘Chimeric antigen receptor T cell therapy has revolutionized cancer treatment,but its efficacy remains constrained by the immunosuppressive tumor microenvironment.Emerging evidence identifies the neuro-immune-cancer axis as a critical modulator of tumor microenvironment dynamics,offering novel opportunities to reshape immune responses.Neural signaling influences chimeric antigen receptor T cell function,yet therapeutic strategies targeting this axis remain largely unexplored.
